Skip to content
Quality Assurance of extended half-life products
Satellite Symposium 2018
Speaker
Titel
Abstract
Presentation
I. Jennings
Quality Assurance of extended half-life products
Related items
Analytical Information :
7
A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Cases :
6
A patient with mild haemophilia A
Haemophilia B and treatment, case study
Haemophilia A and treatment, case study
A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
ECAT Documents :
81
External quality assessment of the manual tilt tube technique for prothrombin time testing: a report from the IFCC-SSC/ISTH Working Group on the Standardization of PT/INR
Comparison of Thrombophilia Assay Results for the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee Plasma Standard from Different External Quality Assessment Providers—for the External Quality Assurance in Thrombosis and Haemostasis Group
Intrinsic Pathway of Coagulation
Inhibitor
Hemophilia B
Hemophilia A
Factor IX Concentrates
Factor IX (FIX)
Factor VIII (FVIII)
Extrinsic Pathway of Coagulation
Desmopressin Acetate (DDAVP)
Coumarin
Control Plasma
Coagulation Factors
Bias
Bethesda Inhibitor Assay (Titer)
Accuracy
Laboratory issues related to the measurement of efanesoctocog alfa webinar 2025
Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study
Lack of grading agreement among international hemostasis external quality assessment programs
Towards harmonization of external qualityassessment/proficiency testing in hemostasis
D-dimer - An International Assessment of the Quality of Laboratory Testing: Implications for D-dimer Use in the Real World
Heparin‐induced thrombocytopenia: An international assessment of the quality of laboratory testing
Analytical variation in factor VIII one‐stage and chromogenic assays: Experiences from the ECAT external quality assessment programme
International external quality assessment for measurements of direct oral anticoagulants: results and recommendations.
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data
The result of the ECAT HIT surveys
The results of the workshop on inhibitor testing
Inhibitor testing: positive or negative? True or False?
A scoring system based on the biological variation
Platelet function testing: laboratory tests and quality control
The results of the ECAT pilot study on FXIII testing
External quality control: a new decade
Results of the interpretative platelet surveys
The laboratory diagnosis of vWD: current insights
Factor VIII Inhibitor Testing, the way to better comparison of test results
Lupus Anticoagulant: Remarkable observations in ECAT surveys
Quality planning in the Haemostasis Laboratory
Case studies in Bleeding disorders
How to use EQA results in the laboratory?
The results of fibrinolytic surveys
Towards diagnostic quality control: a pilot study on acquired inhibitors
External quality control for CoaguChek XS INR monitors
Factor VIII inhibitor testing – a way to comparable test results
The performance of FVIII and FIX measurement in ECAT surveys
Laboratory assays for the measurement of Factor VIII and IX
Gene therapy, the future in hemophilia treatment?
The role of molecular biology in the diagnosis of impaired haemostasis
Quality assurance of the entire diagnostic process
Introduction on Inhibitor Testing
ECAT survey results on ADAMTS13 testing
EQA results for POCT INR testing
ECAT survey results for low levels of Factor VIII
How to measure low levels of Factor VIII and IX
ECAT survey results on direct oral anticoagulant testing
Bleeding webinar 2021, von Willebrand
COVID-19 and Haemostasis webinar 2021
Lupus Anticoagulants webinar 2023
How to use EQA results within the laboratory
ECAT: Towards sustainable EQA
Introduction on Inhibitor Testing
Haemophilia, new development in patient treatment
Is standardisation in coagulation feasible?
Future perspective in quality assurance
Laboratory measurement of extended half-life FVIII
Laboratory measurement of extended half-life FIX
Potency labelling of extended half-life FVIII en FIX products
Treatmentof patients with extended half-life FVIII and FIX products
New developments within ECAT
Factor VIII testing: results of ECAT surveys
One-stage clotting assay versus chromogenic testing in the diagnosis of haemophilia patients
Haemophilia treatment and laboratory testing
New developments in haemophilia treatment
What information does the doctor expect from the laboratory? What kind of services can a laboratory deliver to the physician?
Hemophilia and gene therapy
When Haemostasis Assays Mislead
Guidance for FVIII/FIX Inhibitor testing
Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories
Systematic review and meta-analysis of within-subject and between-subject biological variation data of coagulation and fibrinolytic measurands
International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors
Guidelines :
1
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Haemostatic Cascade :
6
TF Pathway (Extrinsic) with Common Pathway (PT)
Intrinsic Pathway APTT
Coagulation Pathways (All Components)
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Activation of Platelets by Thrombin
Quality Issues :
12
Bivariate Z-score Analysis
An approach for estimating measurement uncertainty in medical laboratories using data from long-term quality control and external quality assessment schemes
A systematic approach for handling unacceptable EQA results
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
External quality control for CoaguChek XS INR monitors
Quality control in the haemostasis laboratory
Long-term evaluation of EQA results
Algorithm A, a new statistical approach for the evaluation of survey results
Quality Assurance of replacement therapy and future perspectives
External Quality Assessment in haemostasis
External quality assessment for Factor VIII and Factor IX
The between-laboratoy variation of Factor VIII inhibitor testing
Surveys and Studies :
3
Emicizumab pilot study, part II
Emicizumab pilot study, part I
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Questions or suggestions?
Clotpedia Support Form
Submit
Success
